SUMITOMO DAINIPPON PHARMA CO., LTD.

SUMITOMO DAINIPPON PHARMA CO., LTD.

Industry:
Healthcare

Founded:
10/1/2005

Address:
6-8 Doshomachi 2-chome, Osaka, Japan Zipcode 541-0045

Country:
Japan

Phone:
81 6 6203 5321

Revenue:
515.95 B
Total Assets:
1.31 T
Total Cash:
193.7 B

Parent organization: Sumitomo Chemical

Sumitomo Dainippon Pharma Co., Ltd._logo

Sumitomo Dainippon Pharma Co., Ltd. manufactures and sells pharmaceuticals, food ingredients and additives, veterinary medicines, diagnostics, and others. The company offers pharmaceutical products, such as therapeutic agents for Parkinson's disease, depression, type 2 diabetes, systemic fungal infection, pruritus, chronic obstructive pulmonary disease, angina pectoris, and arrhythmia. It also provides atypical antipsychotic, antiepileptic, carbapenem antibiotic, and gastroprokine products; and ... Anderson-Fabry disease drugs. In addition, the company offers food ingredients and additives, such as polysaccharides, and seasonings, such as soups or bouillons; and chemical product materials consisting of pharmaceutical excipients, personal care products, coatings and industrial materials, and electronic materials. Further, it provides veterinary medicines for companion animals, primarily dogs and cats; and livestock comprising cattle, swine, poultry, horses, and aquacultured fish. Sumitomo Dainippon Pharma Co., Ltd. has partnerships with Healios K.K.; Keio University; RIKEN; the Center for iPS Cell Research and Application (CiRA); Kyoto University; and Aikomi Co., Ltd., as well as a joint development agreement with SanBio, Inc. It also has a strategic research collaboration agreement with Gain Therapeutics, Inc. for the research and development of structurally targeted allosteric regulators to restore functional activity of defective lysosomal enzymes in rare genetic and demyelinating diseases. The company was formerly known as Dainippon Sumitomo Pharma Co., Ltd. and changed its name to Sumitomo Dainippon Pharma Co., Ltd. in June 2014. Sumitomo Dainippon Pharma Co., Ltd. was founded in 1897 and is headquartered in Osaka, Japan. Sumitomo Dainippon Pharma Co., Ltd. is a subsidiary of Sumitomo Chemical Company, Limited.


Key Executives
Name Title Pay Year Born
Mr. Hiroshi Nomura CEO, Pres & Representative Director N/A 1957(63 years old)
Hisayoshi Kashima Sr. Director & Corp. Controller N/A N/A
Mr. Toru Kimura Ph.D. Exec. VP, Chief Scientific Officer & Representative Director N/A 1960(60 years old)
Ms. Atsuko Higuchi Exec. Officer of Corp. Governance, Corp. Communications & HR N/A N/A
Mr. Hitoshi Odagiri Exec. VP, Exec. Director of Sales & Mktg. Div., Head of Japan Bus. Unit and Rep. Director N/A 1957(63 years old)
Mr. Yoshiharu Ikeda Ph.D. Sr. Exec. Officer & Director N/A 1958(62 years old)
Mr. Hiroyuki Baba Sr. Exec. Officer of Global Data Design Office N/A N/A
Dr. Shigeyuki Nishinaka Ph.D. Sr. Exe. Officer of Global Corp. Strategy, Global Bus. Dev. & International Bus. Mgmt N/A 1965(55 years old)
Mr. Hideyuki Harada Sr. Exec. Officer & Exec. Research Director of Drug Research Division N/A N/A
Tetsuya Uyama Sr. Officer of Legal Disputes N/A N/A

Stock Details

Company's stock symbol is DPM.F. Lastest price : 16.80โ‚ฌ. Total volume :650.00 Click reload if you want to check the lastest price on market!!!
Exchange Frankfurt. Currency in EUR. Market state PREPRE

Sumitomo Dainippon Pharma Co., Ltd. (DPM.F)
Last Price
16.80โ‚ฌ
Change
0.30โ‚ฌ (1.82%)
Volume
650.00

Previous Close16.50
Open16.80
Day Range16.80-16.80
Bid0.00 x 60k
Ask0.00 x 60k
Volume650
Average VolumeN/A
Market Cap6.83B
Beta0.44
52 Week Range9.45-17.30
Trailing P/E15.77
Foward P/EN/A
Dividend (Yield %)1.28%
Ex-Dividend Date2021-09-29
Other Sumitomo Dainippon Pharma Co., Ltd. stocks:
Stock Symbol Exchange Currency Lastest Price Market Change Market Volume
4506.T JPX JPY 2,258.00๏ฟฅ 15.00๏ฟฅ (0.67%) 2.25M


Financial Details

According to Sumitomo Dainippon Pharma Co., Ltd.'s financial reports the company's revenue in 2021 were 515.95B an increase( +6.85%) over the years 2020 revenue that were of 482.73B. In 2021 the company's total earnings were 56.22B while total earnings in 2020 were 40.75B( +40%).


Loading ...


Site Inspections: http://www.ds-pharma.com

Unable to get host informations!!!

Loading ...
Loading ...


More informations about "Sumitomo Dainippon Pharma Co., Ltd." on Search Engine

Sumitomo Dainippon Pharma

May 24, 2021ย ยท Sumitomo Dainippon Pharma. News Releases. May 24, 2021 (PDF/40KB) R&D. Myovant Sciences Receives Positive CHMP Opinion for RYEQO (Relugolix Combination Tablet) for the Treatment of Women With Uterine Fibroids. May 18, 2021 Finances. Posted Video of Investors Meeting Presentation for FY2020 (Year ended March 31, 2021) and Revision of Mid-term ...

Ds-pharma.com Go URL

Sumitomo Dainippon Pharma

Sumitomo Dainippon Pharma Announces Revised Mid-term Business Plan 2022 โ€ฆ

Ds-pharma.com Go URL

Sumitomo Dainippon Pharma

Sumitomo Dainippon Pharma was established 1897, May 14. In 2005, October 1, โ€ฆ

Ds-pharma.com Go URL

Sumitomo Dainippon Pharma

Sumitomo Dainippon Pharma's IR news archives by category. Jun. 03, 2021 โ€ฆ

Ds-pharma.com Go URL

Sumitomo Dainippon Pharma

Sumitomo Dainippon Pharma's presentation materials. Financial Results for FY2010 โ€ฆ

Ds-pharma.com Go URL

Sumitomo Dainippon Pharma

The Sumitomo Dainippon Pharma Group sets the pharmaceutical business as its core โ€ฆ

Ds-pharma.com Go URL

Sumitomo Dainippon Pharma

Sumitomo Dainippon Pharma's organizational chart. (as of April 1, 2021) Sumitomo โ€ฆ

Ds-pharma.com Go URL

Business Units | About Us | Sumitomo Dainippon Pharma

The Sumitomo Dainippon Pharma Group sets the pharmaceutical business as its core activity but also deploys other operations covering food ingredients and chemical product materials, animal health products. In order to deliver innovative and useful pharmaceuticals to people worldwide as well as in Japan we make every effort in applying advanced ...

Ds-pharma.com Go URL

Sumitomo Dainippon Pharma - Wikipedia

Sumitomo Dainippon Pharma Co., Ltd. (ๅคงๆ—ฅๆœฌไฝๅ‹่ฃฝ่–ฌๆ ชๅผไผš็คพ, Dainippon Sumitomo Seiyaku Kabushiki-Gaisha) is a pharmaceutical company based in Japan. Its headquarters are in Chuo-ku, Osaka. The original Dainippon Pharmaceuticals (Dainippon Seiyaku) was established in 1885 by Nagayo Sensai, a graduate of Tekijuku โ€“ the first private medical school in Japan established by Ogata Kลan. It was set up as a wholly private company invested by a number of people in Tokyo and Osaka, with the land and โ€ฆ

En.wikipedia.org Go URL

SUMITOMO DAINIPPON PHARMA CO., LTD. Company Profile ...

OSAKA , OSAKA , 541-0045. Japan. See other locations. Phone. +81-662035321. Company Description. "Healthy bodies, healthy lives," is the goal of Sumitomo Dainippon Pharma (SDP). Through research and development, the Japanese drugmaker produces a wide range of therapeutics in such categories as cardiovascular disease, gastrointestinal disorders ...

Dnb.com Go URL

Dainippon Sumitomo Pharma Company Profile: Stock ...

Mar 31, 2018ย ยท Dainippon Sumitomo Pharma General Information Description. Sumitomo Dainippon Pharma Co Ltd is a specialty and generic drug manufacturing company. Sumitomo's vast majority of sales are generated in North America, followed by Japan. The company's core business is its pharmaceutical products business.

Pitchbook.com Go URL

SUMITOMO DAINIPPON PHARMA CO LT (DNPUF) Stock Price, โ€ฆ

Find the latest SUMITOMO DAINIPPON PHARMA CO LT (DNPUF) stock quote, history, news and other vital information to help you with your stock trading and investing.

Finance.yahoo.com Go URL

Sumitovant Biopharma Created and Launched as Sumitomo ...

Dec 30, 2019ย ยท Today, Sumitomo Dainippon Pharma has more than 6,000 employees worldwide. Additional information about Sumitomo Dainippon Pharma โ€ฆ

Prnewswire.com Go URL

Sumitomo Dainippon Pharma Co., Ltd. Corporate Profile

Corporate Information 1 Corporate Profile Name Sumitomo Dainippon Pharma Co., Ltd. Established May 14, 1897 Date of merger October 1, 2005 Representative Hiroshi Nomura, Representative Director, President and CEO Capitalization 22.4 billion yen (as of September 30, 2019) Fiscal year April 1 โ€ฆ

Ds-pharma.co.jp Go URL

Investor Relations - Sumitomo Dainippon Pharma

Sumitomo Dainippon Pharma's financial data shown in graphs.

Ds-pharma.com Go URL

DNPUF Stock | SUMITOMO DAINIPPON PHARMA Stock Price โ€ฆ

Jan 28, 2021ย ยท DNPUF: Get the latest Sumitomo Dainippon Pharma stock price and detailed information including DNPUF news, historical charts and realtime prices.

Markets.businessinsider.com Go URL

About Sumitomo Dainippon Pharma Oncology

Sumitomo Dainippon Pharma Oncology, Inc. is a developer of novel cancer therapeutics based in the U.S. and a wholly owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd. This U.S. entity, together with the oncology research and development teams in Japan, DSP Cancer Institute, and Oncology Clinical Development Unit, will collectively be known ...

Sdponcology.com Go URL

Contact Us - Sumitomo Dainippon Pharma Oncology

Sumitomo Dainippon Pharma Oncology. We are always interested in hearing from you. Please find contact information below the map, or complete the Inquiries Form to email the appropriate contact. Send us an email

Sdponcology.com Go URL

Sumitomo Dainippon Pharma and Roivant Sciences Sign ...

Oct 31, 2019ย ยท Sumitomo Dainippon Pharma is based on the merger in 2005 between Dainippon Pharmaceutical Co., Ltd., and Sumitomo Pharmaceuticals Co., Ltd. Today, Sumitomo Dainippon Pharma has more than 6,000 employees worldwide. Additional information about Sumitomo Dainippon Pharma is available through its corporate website at https://www.ds-pharma.com ...

Roivant.com Go URL

Sumitomo Pharmaceuticals (Thailand) Co., Ltd. | Overseas ...

Sumitomo Pharmaceuticals (Thailand) Co., Ltd. was established as the subsidiary of Sumitomo Pharmaceuticals Asia Pacific Pte. Ltd. in January 2019 as a part of efforts to strengthen the business foundation in the Southeast Asian region. It has commenced the provision and collection of information on LATUDA ยฎ and MERONEM ยฎ in Thailand.

Ds-pharma.com Go URL